3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Completed
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
2
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
56
Breast Neoplasms
49
Ovarian Neoplasms
31
Triple Negative Breast Neoplasms
27
Endometrial Neoplasms
25
Lung Neoplasms
24
Fallopian Tube Neoplasms
22
Neoplasm Metastasis
21
Squamous Cell Carcinoma of Head and Neck
19
Parkinson Disease 4, Autosomal Dominant Lewy Body
18
Neoplasms
14
Esophageal Squamous Cell Carcinoma
12
Esophageal Neoplasms
12
Carcinoma, Ovarian Epithelial
9
Stomach Neoplasms
8
Head and Neck Neoplasms
8
Colorectal Neoplasms
8
Carcinoma
7
Adenocarcinoma Of Esophagus
7
Peritoneal Neoplasms
6
Adenocarcinoma
6
Uterine Cervical Neoplasms
5
Melanoma
5
Oropharyngeal Neoplasms
4
Cholangiocarcinoma
4
Carcinoma, Transitional Cell
4
Urinary Bladder Neoplasms
3
Small Cell Lung Carcinoma
3
Recurrence
3
Pancreatic Neoplasms
3
Interventions
pembrolizumab
2
durvalumab
2
Paclitaxel
2
Nivolumab
2
Ipilimumab
2
Doxorubicin
2
zanidatamab
1
veliparib
1
tucatinib
1
trilaciclib
1
trebananib
1
trastuzumab duocarmazine
1
talazoparib
1
spartalizumab
1
selinexor
1
sarilumab
1
pexidartinib
1
pertuzumab
1
pazopanib
1
patritumab
1
olaparib
1
niraparib
1
neratinib
1
ganitumab
1
dostarlimab
1
cemiplimab
1
balstilimab
1
abemaciclib
1
Trastuzumab
1
Standard of Care
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Hemangiosarcoma
×
Paclitaxel
×
90 days
×
Clear all
NCT01042379
2026-05-06
I-SPY
QuantumLeap Healthcare Collaborative
Phase 2
Recruiting
5,000 enrolled
NCT01303497
2026-03-13
ANGIO-TAX+
Centre Oscar Lambret
Phase 2
Completed
70 enrolled